Short answer
Dyne Therapeutics, Inc. (DYN) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$194M
- −79.1% YoY · −8.4% QoQ
- EPS (diluted)
- −$1.08
- −50.0% YoY · +0.0% QoQ
Source: XBRL data from the Dyne Therapeutics, Inc. (DYN) Q3 2026 10-Q on SEC EDGAR. USD.
Dyne Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales since inception
- Net loss $193.6M vs $108.0M YoY, operating margin not meaningful due to zero revenue
- Best-performing program: z-rostudirsen R&D $66.9M vs $22.7M, worst: z-basivarsen $32.8M vs $37.9M
- Cash, equivalents and marketable securities $1.134B; operating cash use $452.7M vs $291.4M YoY
- July offering raised $404.9M; potential z-rostudirsen launch Q1 2027, cash runway into Q2 2028
Risk Factors
- Newly added regulatory risk, BIOSECURE Act restrictions could disrupt Chinese supplier relationships and increase manufacturing costs
- Most material update, DMD competition intensified after Avidity’s September 2026 priority review for delpacibart zotadirsen
- Clinical risk, FDA previously placed z-rostudirsen’s IND on hold pending additional clinical and non-clinical information
- Operational risk, reliance on single or limited suppliers for Fabs, linkers and payloads creates interruption exposure
- Financial risk, $1.134 billion liquidity expected to fund operations through second quarter 2028, subject to plan assumptions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dyne Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.